Abiopharma

🔍 Isner Joshua (Executive)

Company: AXON ENTERPRISE, INC. (AXON)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Sold 15,704 shares of Common Stock at $615.59 per share (Direct)
  Date: 2026-08-13 | Code: F | equity_swap_involved: 0 | shares_owned_after: 231,620.55 | transaction_form_type: 4 | Footnotes: F1
• Acquired 67,910 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 299,530.55 | transaction_form_type: 4 | Footnotes: F2
• Acquired 14,218 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 313,748.55 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Securities disposed represent securities withheld to settle the reporting person's tax liability resulting from the vesting of restricted stock units.
• F2: The transaction consists of performance-based restricted stock units (collectively, "XSUs") granted on December 22, 2023 pursuant to the Axon Enterprise, Inc. 2024 eXponential Stock Plan, for which the performance conditions for the fourth tranche of XSUs (the "Tranche") were certified by the issuer's Compensation Committee of the Board of Directors on August 16, 2026 as having been met. The Tranche will vest on December 1, 2026, subject to continued employment through such date. Following the vesting, the shares deliverable for the Tranche are subject to a minimum holding period until the earlier of (i) December 31, 2030 and (ii) the date on which a subsequent tranche of XSUs vests, excluding shares withheld or sold to cover applicable taxes.
• F3: This award represents a supplemental grant approved by the Compensation Committee to implement the executive compensation program as intended with respect to the treatment of future XSP tranches.